Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.

The novel coronavirus SARS-CoV2, which causes COVID-19, has resulted in the death of nearly 4 million people within the last 18 months. While preventive vaccination and monoclonal antibody therapies have been rapidly developed and deployed, early in the pandemic the use of COVID-19 convalescent plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Natasha M, Janaka, Sanath Kumar, Hartman, William, Stramer, Susan, Goodhue, Erin, Weiss, John, Evans, David T., Connor, Joseph P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452094/
https://www.ncbi.nlm.nih.gov/pubmed/34545365
http://dx.doi.org/10.1101/2021.09.14.460394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452094/
https://www.ncbi.nlm.nih.gov/pubmed/34545365
http://dx.doi.org/10.1101/2021.09.14.460394

Ejemplares similares